Genomic Valley Biotech Ltd

Genomic Valley Biotech Ltd: Trading window closed from Oct 1, 2026 until 48 hours after the announcement of the unaudited financial results for the quarter and half year ended Sept 30, 2026.

Standalone results approved

• Approved standalone unaudited results for quarter ended 30 June 2026.

Limited review report

• Limited review report from Andros & Co. enclosed with the results.

Meeting Details

• Board meeting on Friday, 14 August 2026 at the company's corporate office.

Key Agenda Items

• Approve unaudited standalone financial results for quarter ended 30 June 2026.
• Consider any other matter with permission of the chair.

Other Notes

• Trading window closed from 1 July 2026 until 48 hours after results for insiders.

Dematerialisation processing

• Dematerialisation requests processed in the quarter ended June 2026 and confirmed to the depositories.
• Securities dematerialised have been listed on the exchanges where earlier securities are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled; depositories named as registered owners within 15 days.

Trading Window Closure

• Trading window closed from 01 July 2026 for the unaudited June 30, 2026 results.
• Closed until 48 hours after results are announced and generally available.
• During closure, employees, directors, KMPs and designated persons and their immediate relatives must not trade.
• Board meeting date to declare unaudited results will be intimated in due course.